Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,412.00
Bid: 12,410.00
Ask: 12,414.00
Change: 14.00 (0.11%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,482.00
Low: 12,400.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HSBC lifts AstraZeneca target price on haematological cancer forecasts

Mon, 04th Jan 2016 13:01

(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas.AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due upon approval by the US of the take-over target's lead cancer drug acalabrutinib or by end-2018, whichever was soonest.With Acerta's owners having the option to sell the remaining stake to the FTSE 100 company for $3bn, the broker said it assumed this would occur in 2018, as it saw no rationale for the option to be exercised sooner rather than later.Acalabrutinib, aka ACP-196, could prove to be "best-in-class" monotherapy, the bank said.Phase II clinical data and ongoing phase III trials also meant that acalabrutinib was likely to be very competitive versus Johnson & Johnson and AbbVie's Imbruvica, currently the only drug on the market that inhibits the BTK enzyme and can treat haematological cancers.Shift towards combination therapies justifies price tagAstraZeneca has already signed a wide-ranging collaboration with Celgene to jointly develop immuno-oncology treatments for haematological cancers.Hence, "were the standard of care in some haematological cancers to move to the combination of a BTK inhibitor (such as acalabrutinib) and an anti-PDL1 (such as AstraZeneca's durvalumab), then by acquiring Acerta, AstraZeneca would gain two thirds of the overall economics of the combination (versus 30-50% of durvalumab monotherapy)," the analysts wrote."In our view, that helps justify the potential $7bn price tag for acquiring a company whose main asset has not yet been approved, not even completed phase III development."Despite including revenues from this and other recent acquisitions, 2023 revenue forecasts of circa $37bn were still around $8bn shy of AstraZeneca's 2023 target announced during the failed Pfizer bid process, the analysts noted, though this was increasingly likely to be seen as an aspirational target that diminishes in relevance through time.AZN's target price was lifted to 4,910p from the previous 4,770p, with a 'buy' rating reiterated.
More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.